CSIMarket
 
Maxcyte inc   (MXCT)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $4.3100 $0.11 2.619%
Day's High: $4.39 Week Perf: 8.56 %
Day's Low: $ 4.15 30 Day Perf: -7.71 %
Volume (M): 859 52 Wk High: $ 5.55
Volume (M$): $ 3,704 52 Wk Avg: $4.29
Open: $4.19 52 Wk Low: $2.45



 Market Capitalization (Millions $) 442
 Shares Outstanding (Millions) 102
 Employees -
 Revenues (TTM) (Millions $) 41
 Net Income (TTM) (Millions $) -38
 Cash Flow (TTM) (Millions $) 35
 Capital Exp. (TTM) (Millions $) 4

Maxcyte Inc
Maxcyte Inc. is a biotechnology company that specializes in cell engineering and flow electroporation technology. The company is focused on developing innovative solutions for drug discovery, cell and gene therapy, and biomanufacturing. Maxcyte's proprietary technology allows for high levels of transfection efficiency and cell engineering, making it an attractive option for researchers and pharmaceutical companies looking to develop new therapies and improve biomanufacturing processes. The company also offers contract development and manufacturing services, providing support to clients in the development and production of cell-based therapies. Overall, Maxcyte Inc. plays a significant role in advancing the field of cell engineering and facilitating the development of novel therapies.


   Company Address: 9713 Key West Avenue Rockville 20850 MD
   Company Phone Number: 944-1700   Stock Exchange / Ticker: NASDAQ MXCT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Maxcyte Inc

Maxcyte Inc. Sees Revenue Surge, But Fails to Reach Profitability Goals in Q4 2023

Maxcyte Inc, a leading cell-engineering focused company, recently announced its fourth quarter and full year financial results for 2023. The company reported a surge in revenue by 26.087% to $15.66 million from the same reporting period a year before. However, it also experienced diminishing returns with a net shortfall of $-0.05 per share.
Despite the positive revenue growth, Maxcyte Inc's shares have gone down by -15.63% in the past 5 trading days and -14.35% from a year ago. Currently, the company's shares are trading on the NASDAQ by -8.4% below its 52 week average.

Licensing Agreement

MaxCyte Inc. and Wugen Collaborate to Revolutionize Manufacturing of Cell Therapies for Cancer Treatment

Published Tue, Jan 30 2024 1:05 PM UTC

MaxCyte and Wugen Partner to Accelerate Manufacturing of Cell Therapies for Cancer TreatmentMaxCyte Inc. and Wugen Inc. have recently announced a strategic platform license agreement aimed at expediting the scale-up of clinical and commercial manufacturing of Wugen's investigational allogeneic, off-the-shelf cell therapies for hematologic and solid tumor cancers. Under this ...

Licensing Agreement

MaxCyte and Imugene Forge Groundbreaking Partnership to Revolutionize Cancer Immunotherapy Programs

Published Tue, Jan 23 2024 1:05 PM UTC

In a groundbreaking move set to transform the landscape of cancer immunotherapy, MaxCyte, a leading cell-based medicines and life sciences company, has recently signed a strategic platform license agreement with Imugene, a clinical-stage immuno-oncology company. This impactful collaboration aims to advance their cancer immunotherapy programs, particularly focusing on the dev...

Partnership

MaxCyte and Lion TCR: A Dynamic Union Aiming to Globalize Innovative TCR-T Cell Therapies

Published Wed, Jan 3 2024 1:05 PM UTC

MaxCyte Inc., a leading global company specialized in scalable high-performance cell engineering, and Lion TCR, a clinical-stage biotechnology company focused on the development of T cell receptor (TCR) T cell therapies, have recently announced a strategic partnership. This union aims to bolster the global expansion of Lion TCR's TCR-T cell pipeline, a groundbreaking therape...

Management Changes

MaxCyte Faces Financial Challenges as CEO Announces Retirement; Company Sets Focus on Revenue Guidance Update for 2023

Published Mon, Dec 11 2023 9:06 PM UTC

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
MaxCyte Inc, a leading cell engineering company, recently announced a significant change in its management as Doug Doerfler, the current President and CEO, is set to retire effective December 31, 2023. However, Doerfler will continue to serve as an advisor to MaxCyte, ensuring a smooth transition in ...






 

Maxcyte Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Maxcyte Inc does not provide revenue guidance.

Earnings Outlook
Maxcyte inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com